MaxCyte, Inc.

11:15 AM - 11:30 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
CARMA(TM) is an mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. The CARMA therapeutic platform utilizes PBMCs and can be manufactured in one day; dramatically reducing the time, complexity and cost of autologous cell therapies. MCY-M11, the first CARMA drug candidate, is a mesothelin-targeting CAR therapy being tested in a Phase I clinical trials in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.

In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharma partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its instruments worldwide, including with all top 10 global biopharmas. The Company now has 80+ partnered program licenses in cell therapy with 45+ licensed for clinical use. www.maxcyte.com
Ticker:
MXCT
Exchange:
LSE | AIM
Company Type:
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
1998
Main Therapeutic Focus:
Lead Product in Development:
MCY-M11
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided